Antisense-based cancer therapeutics: are we there yet?

Expert Opinion on Emerging Drugs
Elizabeth Rose RayburnRuiwen Zhang

Abstract

Despite significant advances that have been made in recent years, there is still an urgent need for novel, more effective and less toxic therapeutics for human cancer. Among many new molecular therapeutics being explored for cancer therapy, antisense oligonucleotides are a promising nucleic acid-based approach, with numerous antisense agents being evaluated in preclinical studies and several anticancer antisense drugs in clinical trials. Although there are still a few problems facing the development of antisense strategies for cancer therapy, with progress made in chemical modifications, target selection and drug delivery systems, antisense oligonucleotides are emerging as a novel approach to cancer therapy used alone or in combination with conventional treatments such as chemotherapy and radiation therapy.

References

Jan 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·P C Zamecnik, M L Stephenson
Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·R Y Walder, J A Walder
Apr 6, 1995·Nature·A M KriegD M Klinman
Jan 1, 1994·Antisense Research and Development·U M SarmientoR Narayanan
Nov 22, 1996·Biochemical Pharmacology·Q ZhaoS Agrawal
May 21, 1998·Antisense & Nucleic Acid Drug Development·S Agrawal, Q Zhao
Sep 22, 1998·Antisense & Nucleic Acid Drug Development·S T Crooke
May 12, 2000·Biochimica Et Biophysica Acta·S T Crooke
Jun 2, 2000·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·A Ray, B Nordén
Sep 29, 2000·Pharmacology & Therapeutics·C Garcia-ChaumontJ Bolard
Jul 12, 2001·Antisense & Nucleic Acid Drug Development·M S WebbD J Kornbrust
Sep 26, 2001·Neoplasia : an International Journal for Oncology Research·T ZellwegerM E Gleave
Feb 28, 2002·Annual Review of Immunology·Arthur M Krieg
Jun 18, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Vikram AroraPatrick L Iversen
Aug 30, 2002·Biochemical and Biophysical Research Communications·Jean-Rémi BertrandClaude Malvy
Nov 8, 2002·British Medical Bulletin·Johann S de Bono, Eric K Rowinsky
Feb 5, 2003·Advanced Drug Delivery Reviews·Virginie EscriouPierre Wils
Mar 7, 2003·Il Farmaco·Ernst Urban, Christian R Noe
Mar 18, 2003·European Journal of Nuclear Medicine and Molecular Imaging·Judy WangRaymond M Reilly
Apr 16, 2003·European Journal of Biochemistry·Jens Kurreck
Apr 16, 2003·Gynecologic Oncology·A M OzaUNKNOWN NCIC Clinical Trials Group Study (NCIC IND.116)
May 7, 2003·Cancer·Douglas G GoldKathryn E Dusenbery
May 10, 2003·Brain Research. Brain Research Reviews·Dirk Van OekelenJosée E Leysen
Jul 29, 2003·Journal of Pharmaceutical Sciences·Melanie A Lysik, Susanna Wu-Pong
Sep 18, 2003·Proceedings of the National Academy of Sciences of the United States of America·Zhuo ZhangRuiwen Zhang
Oct 7, 2003·Oncogene·Annamaria BiroccioGabriella Zupi
Nov 19, 2003·Current Opinion in Oncology·James E Wooldridge, George J Weiner
Dec 10, 2003·Oncogene·Nicholas M Dean, C Frank Bennett
Dec 23, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M LahnD Ma
Jan 31, 2004·Annals of the New York Academy of Sciences·Antonina S RaitEsther H Chang
Jan 31, 2004·Annals of the New York Academy of Sciences·Jon T Holmlund
Feb 13, 2004·The Journal of Biological Chemistry·Hongjiang WuStanley T Crooke
Feb 24, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Zhuo ZhangRuiwen Zhang
Apr 24, 2004·Oligonucleotides·Lingamanaidu V RavichandranEric G Marcusson
Jun 4, 2004·Expert Opinion on Biological Therapy·Kim N Chi, Martin E Gleave
Jul 10, 2004·Biochemical Pharmacology·Anna Astriab-FisherPiet Herdewijn
Jul 17, 2004·Annual Review of Biomedical Engineering·Charles M Roth, Sumati Sundaram

❮ Previous
Next ❯

Citations

Jan 25, 2008·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·J Eugene Lee, Ronald T Raines
Jun 26, 2009·Expert Opinion on Drug Delivery·Xiubo ZhaoJian R Lu
May 2, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yoon Shin ParkVictor C Yang
Aug 21, 2007·Journal of Controlled Release : Official Journal of the Controlled Release Society·Eytan A KlausnerShridhar V Andurkar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.